Skip to content
★ Sign in to follow
JD

John David Harris

Executive
Total declarations
3
Company
1
▲ Purchases (2 ops.)
€9,301
▼ Sales (0 ops.)
—

Latest filing published 11 Aug 2016 for CERENOME, INC., €4,537.

Insider track record

Disclosed buys
2
Disclosed sells
0
Signal history

Closed purchases

Market purchases
2
Positive at T+90
0%
Median T+90
-28.2%

Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

  • Filed 11 Aug 2016 · 3742 days ago · €4,537
    -82.0%
    Entry US$384,375.00 · Close at T+365 US$69,375.00
  • Filed 16 May 2016 · 3829 days ago · €4,764
    -71.2%
    Entry US$624,375.00 · Close at T+365 US$180,000.00

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

John David Harris: trading record in brief

John David Harris is a declared insider of Cerenome, Inc., with filings sourced from SEC (Form 4). In total, 3 filings cover trades dated from 13 May 2016 to 10 August 2016.

On the market, this insider has only ever bought: 2 purchases, €9,301 in total. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 1 share grant.

The latest filing, published on 11 August 2016, reports an open-market purchase of €4,537 in Cerenome, Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.

Companies and markets linked to John David Harris

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations3 total
  • ▲
    VP and GM Cell TherapyExecutivesCerenome, Inc.
    5,075 USD18SEC
    2,500 shares@ US$2.0348.8% of flowCommon StockSEC:0001140361-16-075923:0
    Canonical exit: 8 Nov 2016 (T+90)
  • ◆
    VP and GM Cell TherapyExecutivesCerenome, Inc.
    0SEC
    2,500 sharesCommon StockSEC:0001140361-16-069909:0
  • ▲
    VP and GM Cell TherapyExecutivesCerenome, Inc.
    5,420 USD16SEC
    2,000 shares@ US$2.7151.2% of flowCommon StockSEC:0001140361-16-065745:0
    Canonical exit: 11 Aug 2016 (T+90)

3 of 3 declarations